Nickel/Cobalt-Catalyzed C(sp<sup>3</sup>)–C(sp<sup>3</sup>) Cross-Coupling of Alkyl Halides with Alkyl Tosylates
作者:Kimihiro Komeyama、Takuya Michiyuki、Itaru Osaka
DOI:10.1021/acscatal.9b03352
日期:2019.10.4
The C(sp3)–C(sp3) cross-coupling of alkyl halides with alkyl tosylates has been developed by employing a combination of nickel and nucleophilic cobalt catalysts in the presence of a manganese reductant. This method provides a straightforward route to a diverse set of not only secondary–primary but also primary–primary C(sp3)–C(sp3) linkages under mild conditions without using alkyl-metallic reagents
Palladium-Catalyzed Hydroaminocarbonylation of Alkenes with Amines: A Strategy to Overcome the Basicity Barrier Imparted by Aliphatic Amines
作者:Guoying Zhang、Bao Gao、Hanmin Huang
DOI:10.1002/anie.201502405
日期:2015.6.22
A novel and efficient palladium‐catalyzed hydroaminocarbonylation of alkenes with aminals has been developed under mild reaction conditions, and allows the synthesis of a wide range of N‐alkyl linear amides in good yields with high regioselectivity. On the basis of this method, a cooperative catalytic system operating by the synergistic combination of palladium, paraformaldehyde, and acid was established
The weak acid has been identified as an efficient basicity-mask to overcome the basicitybarrierimparted by aliphaticamines in the Pd-catalyzed hydroaminocarbonylation, which enables both aromatic and aliphaticamines to be applicable in the palladium-catalyzedhydroaminocarbonylation reaction. Notably, by using this protocol, the marketed herbicide of Propanil and drug of Fentanyl could be easily
[EN] TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF<br/>[FR] COMPOSÉS MODULATEURS DE TLR2, COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS
申请人:AXIAL THERAPEUTICS INC
公开号:WO2021242923A1
公开(公告)日:2021-12-02
The present disclosure relates to compounds which modulate the activity of Toll-like receptor (TLR) proteins, including agonists or activators, partial agonists, and antagonists. Of particular interest of compounds that modulate the activity of TLR2, as well as methods of using such compounds to treat cancer and other disorders associated with a TLR2 pathway.